Use of nintedanib in patients with idiopathic pulmonary fibrosis: Initial Indian experience

Nintedanib is a tyrosine kinase inhibitor which has shown to reduce the progression of idiopathic pulmonary fibrosis (IPF). [...]a follow-up PFT was available in only 12/20 patients. [...]significant numbers (6/25) of patients prescribed nintedanib could not commence or continue it due to high costs...

Full description

Saved in:
Bibliographic Details
Published in:Lung India 2019-09, Vol.36 (5), p.465-466, Article 465
Main Authors: Mullerpattan, Jai, Porwal, Sana, Sarkar, Trina, Wagh, Haresh, Udwadia, Zarir
Format: Article
Language:English
Subjects:
Drug dosages
Patients
Pulmonary fibrosis
Research Letters
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Nintedanib is a tyrosine kinase inhibitor which has shown to reduce the progression of idiopathic pulmonary fibrosis (IPF). [...]a follow-up PFT was available in only 12/20 patients. [...]significant numbers (6/25) of patients prescribed nintedanib could not commence or continue it due to high costs.
ISSN:0970-2113
0974-598X
DOI:10.4103/lungindia.lungindia_195_19